MDACC Study No:2010-0356 ( NCT No: NCT01136967)
Title:An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of Levatinib in
Previously Treated Subjects With Unresectable Stage III or Stage IV
Principal Investigator:Rodabe N. Amaria
Treatment Agent:E7080
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if Lenvatinib can help to
control advanced melanoma that has not responded to treatment. The safety of
the study drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:E7080
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eisai
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Rodabe N. Amaria
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults